Latest news and press releases about Apogee Therapeutics, Inc. (APGE): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders.
Price
| Price | $135.07 |
| Market Cap | $8.4B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 8.53 |
| EV / EBITDA | -28.35 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -29.88% |
| Return on Invested Capital | -25.23% |
| Return on Assets | -22.04% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AAPG · CELC · CGON · CNTA · IRON · LEGN · RARE
Explore sector: Healthcare · Biotechnology
More sections of APGE: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks